AbbVie Elahere — Net revenues increased by 7.1% to $182.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 23.0%, from $148.00M to $182.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful market adoption and growing demand for the therapy, while a decrease may signal increased competition or loss of market share.
This metric represents the total gross sales of the Elahere product line minus returns, allowances, and rebates. It serv...
Comparable to revenue metrics for specific oncology assets or specialty pharmaceutical products at peer biopharmaceutical companies.
abbv_segment_elahere_net_revenues| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $64.00M | $128.00M | $139.00M | $148.00M | $179.00M | $159.00M | $170.00M | $182.00M |
| QoQ Change | — | — | — | — | — | — | — | — | — | +100.0% | +8.6% | +6.5% | +20.9% | -11.2% | +6.9% | +7.1% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | +179.7% | +24.2% | +22.3% | +23.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.